NDLI: Serum Anti-BPAG1 Auto-Antibody Is a Novel Marker for Human Melanoma

Content Provider	PubMed Central
Author	Shimbo, Takashi Tanemura, Atsushi Yamazaki, Takehiko Tamai, Katsuto Katayama, Ichiro Kaneda, Yasufumi
Editor	Vladimir, Brusic
Abstract	Malignant melanoma is one of the most aggressive types of tumor. Because malignant melanoma is difficult to treat once it has metastasized, early detection and treatment are essential. The search for reliable biomarkers of early-stage melanoma, therefore, has received much attention. By using a novel method of screening tumor antigens and their auto-antibodies, we identified bullous pemphigoid antigen 1 (BPAG1) as a melanoma antigen recognized by its auto-antibody. BPAG1 is an auto-antigen in the skin disease bullous pemphigoid (BP) and anti-BPAG1 auto-antibodies are detectable in sera from BP patients and are used for BP diagnosis. However, BPAG1 has been viewed as predominantly a keratinocyte-associated protein and a relationship between BPAG1 expression and melanoma has not been previously reported. In the present study, we show that bpag1 is expressed in the mouse F10 melanoma cell line in vitro and F10 melanoma tumors in vivo and that BPAG1 is expressed in human melanoma cell lines (A375 and G361) and normal human melanocytes. Moreover, the levels of anti-BPAG1 auto-antibodies in the sera of melanoma patients were significantly higher than in the sera of healthy volunteers (p<0.01). Furthermore, anti-BPAG1 auto-antibodies were detected in melanoma patients at both early and advanced stages of disease. Here, we report anti-BPAG1 auto-antibodies as a promising marker for the diagnosis of melanoma, and we discuss the significance of the detection of such auto-antibodies in cancer biology and patients.
Related Links	http://dx.doi.org/10.1371/journal.pone.0010566
Starting Page	10566
File Format	PDF
ISSN	19326203
e-ISSN	19326203
Journal	PLoS ONE
Issue Number	5
Volume Number	5
Language	English
Publisher	Public Library of Science
Publisher Date	2010-05-01
Access Restriction	Open
Rights Holder	Public Library of Science
Subject Keyword	Biochemistry, Genetics and Molecular Biology(all) Agricultural and Biological Sciences(all) Medicine(all) Research in Higher Education
Content Type	Text
Resource Type	Article
Subject	Multidisciplinary

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

C-Terminal Tensin-Like Protein Is a Novel Prognostic Marker for Primary Melanoma Patients

Serum Amyloid A Is a Marker for Pulmonary Involvement in SystemicSclerosis

Down-Regulation of miR-92 in Human Plasma Is a Novel Marker for Acute Leukemia Patients

Serum Antibodies against CD28– A New Potential Marker of Dismal Prognosis in Melanoma Patients

Serum Soluble HLA-E in Melanoma: A New Potential Immune-Related Marker in Cancer

Secretome-Based Identification of ULBP2 as a Novel Serum Marker for Pancreatic Cancer Detection

Cys34-Cysteinylated Human Serum Albumin Is a Sensitive Plasma Marker in Oxidative Stress-Related Chronic Diseases

Modulation of the Human T Cell Response by a Novel Non-Mitogenic Anti-CD3 Antibody

L1TD1 Is a Marker for Undifferentiated Human Embryonic Stem Cells

Serum Anti-BPAG1 Auto-Antibody Is a Novel Marker for Human Melanoma

Similar Documents

C-Terminal Tensin-Like Protein Is a Novel Prognostic Marker for Primary Melanoma Patients

Serum Amyloid A Is a Marker for Pulmonary Involvement in SystemicSclerosis

Down-Regulation of miR-92 in Human Plasma Is a Novel Marker for Acute Leukemia Patients

Serum Antibodies against CD28– A New Potential Marker of Dismal Prognosis in Melanoma Patients

Serum Soluble HLA-E in Melanoma: A New Potential Immune-Related Marker in Cancer

Secretome-Based Identification of ULBP2 as a Novel Serum Marker for Pancreatic Cancer Detection

Cys34-Cysteinylated Human Serum Albumin Is a Sensitive Plasma Marker in Oxidative Stress-Related Chronic Diseases

Modulation of the Human T Cell Response by a Novel Non-Mitogenic Anti-CD3 Antibody

L1TD1 Is a Marker for Undifferentiated Human Embryonic Stem Cells

Serum Anti-BPAG1 Auto-Antibody Is a Novel Marker for Human Melanoma